Effectiveness of ranibizumab in specific diseases in clinical practice – case studies
Article Sidebar
Main Article Content
Abstract
Age-related macular degeneration, diabetic macular edema and retinal vein occlusion are main retinal diseases leading to vision impairment and having undoubtedly strong influence on patients’ quality of life. Treatment based on intravitreal injections of ranibizumab is a breakthrough therapy in ophthalmology. Access to early diagnosis and treatment can help achieve a therapeutic success and even prevent complete vision loss. Thanks to availability of intravitreal injections we are able to stop the progress of the disease and restore patients’ visual acuity. This gives patients hope to maintain they everyday activity.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Omulecki W. Raport Zatrzymać epidemię ślepoty 2011 pod patronatem Stowarzyszenia Zwyrodnienia Plamki Związanego z Wiekiem (AMD) i Polskiego Towarzystwa Okulistycznego.
3. Kański JJ, Bowling B. Okulistyka kliniczna. Elsevier Urban & Partner, Wrocław 2013: 609-11.
4. Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophtalmol. 2008; 2(4): 919-30.
5. Kubicka-Trząska A. Doszklistkowe iniekcje ranibizumabu w leczeniu cukrzycowego obrzęku plamki. Klinika Okulistyczna. 2010; 10-12: 333.
6. Szaflik M, Szaflik J. Diagnostyka i postępowanie terapeutyczne w obrzęku plamki w przebiegu zakrzepu naczyń żylnych siatkówki. Okulistyka. 2014; 4: 27.
7. Borucka AI, Sidorowicz E. Zastosowanie afliberceptu w leczeniu obrzęku plamki wtórnego do zakrzepu żyły środkowej siatkówki – opis przypadków. Okulistyka. 2015, wydanie specjalne czerwiec 2015; 36-42.
8. Wells JA, Glassman AR, Ayala AR et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015; 372(13): 1193-203.
9. Latalska M, Dolar-Szczasny J, Święch-Zubilewicz A et al. Results of Intravitreal Aflibercept Treatment in Patients with Diabetic Macular Edema – Preliminary Report. Okulistyka. 2015, wydanie specjalne czerwiec 2015; 27-30.
10. Zasady postępowania w cukrzycowym obrzęku plamki – wytyczne PTO (2014).
11. Agarwal A, Afridi R, Hassan M. Novel Therapies in Development for Diabetic Macular Edema. Curr Diab Rep. 2015; 15(10): 75.
12. Dirani A, Mantel I, Ambresin A. Recurrent Macular Edema in Central Retinal Vein Occlusion Treated with Intravitreal Ranibizumab using a Modified Treat and Extend Regimen. Klin Monbl Augenheilkd. 2015; 232(4): 538-41.
13. Yumusak E, Buyuktortop N, Ornek K. Early results of dexamethasone implant, ranibizumab, and triamcinolone in macular edema due to branch retinal vein occlusion. Eur J Ophthalmol. 2015 [Epub ahead of print].
14. Heier JS, Campochiaro PA, Yau l et al. Ranibizumab for macular edema due to retinal vein occlusion: long term follow-up in the Horizon Trial. Ophthalmology. 2012; 119(4): 802-9.